BRPI0309631A8 - vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4 - Google Patents

vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4 Download PDF

Info

Publication number
BRPI0309631A8
BRPI0309631A8 BRPI0309631A BRPI0309631A BRPI0309631A8 BR PI0309631 A8 BRPI0309631 A8 BR PI0309631A8 BR PI0309631 A BRPI0309631 A BR PI0309631A BR PI0309631 A BRPI0309631 A BR PI0309631A BR PI0309631 A8 BRPI0309631 A8 BR PI0309631A8
Authority
BR
Brazil
Prior art keywords
dengue
deletion
utr
trivial
nucleotides
Prior art date
Application number
BRPI0309631A
Other languages
English (en)
Inventor
R Murphy Brian
Falgout Barry
Blaney Joseph
Hanley Kathryn
Markoff Lewis
S Whitehead Stephen
Original Assignee
The Government Of The Us Secretary Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The Us Secretary Department Of Health And Human Services filed Critical The Government Of The Us Secretary Department Of Health And Human Services
Publication of BRPI0309631A2 publication Critical patent/BRPI0309631A2/pt
Publication of BRPI0309631A8 publication Critical patent/BRPI0309631A8/pt
Publication of BRPI0309631B1 publication Critical patent/BRPI0309631B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
BRPI0309631-9A 2002-05-03 2003-04-25 Composição imunogênica tetravalente compreendendo vírus atenuado contra dengue e vacina tetravalente compreendendo a dita composição BRPI0309631B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37786002P 2002-05-03 2002-05-03
US60/377,860 2002-05-03
US43650002P 2002-12-23 2002-12-23
US60/436,500 2002-12-23
PCT/US2003/013279 WO2003092592A2 (en) 2002-05-03 2003-04-25 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

Publications (3)

Publication Number Publication Date
BRPI0309631A2 BRPI0309631A2 (pt) 2016-11-01
BRPI0309631A8 true BRPI0309631A8 (pt) 2018-09-25
BRPI0309631B1 BRPI0309631B1 (pt) 2021-07-20

Family

ID=29406814

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0309631-9A BRPI0309631B1 (pt) 2002-05-03 2003-04-25 Composição imunogênica tetravalente compreendendo vírus atenuado contra dengue e vacina tetravalente compreendendo a dita composição

Country Status (15)

Country Link
US (7) US7517531B2 (pt)
EP (5) EP2338508B1 (pt)
JP (1) JP4977811B2 (pt)
AT (1) ATE481982T1 (pt)
BR (1) BRPI0309631B1 (pt)
CA (1) CA2483653C (pt)
CY (1) CY1120558T1 (pt)
DE (1) DE60334310D1 (pt)
DK (2) DK1554301T3 (pt)
ES (2) ES2355719T3 (pt)
HU (1) HUE037330T2 (pt)
PT (2) PT1554301E (pt)
SI (2) SI1554301T1 (pt)
TR (1) TR201806655T4 (pt)
WO (1) WO2003092592A2 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2355719T3 (es) 2002-05-03 2011-03-30 The United States Government As Represented By The Department Of Health And Human Services Vacuna contra el dengue que contiene una deleción común de 30 nucleótidos en la utr en 3' del dengue tipos 1 y 2.
RU2465326C2 (ru) 2005-04-24 2012-10-27 Санофи Пастер Байолоджикс Ко Рекомбинантные флавивирусные вакцины
JP4549224B2 (ja) * 2005-04-25 2010-09-22 出光ユニテック株式会社 透明ポリプロピレン系樹脂シートの製造方法、透明ポリプロピレン系樹脂シート、及び成形品、並びに透明ポリプロピレン系樹脂シートからなる成形品の白化防止方法、及び温度判別方法
EP1893637B1 (en) * 2005-06-17 2016-01-06 Sanofi Pasteur Dengue serotype 1 attenuated strain
CA2611954C (en) 2005-06-17 2014-01-28 Sanofi Pasteur Dengue serotype 2 attenuated strain
CA2616026A1 (en) * 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
US8337860B2 (en) 2006-08-15 2012-12-25 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Development of dengue virus vaccine components
AU2013263788B2 (en) * 2006-08-15 2016-05-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of dengue virus vaccine components
AU2016219680B2 (en) * 2006-08-15 2018-08-09 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of dengue virus vaccine components
TWI472639B (zh) 2009-05-22 2015-02-11 Samsung Display Co Ltd 薄膜沉積設備
JP5623786B2 (ja) 2009-05-22 2014-11-12 三星ディスプレイ株式會社Ｓａｍｓｕｎｇ Ｄｉｓｐｌａｙ Ｃｏ．，Ｌｔｄ． 薄膜蒸着装置
KR101117719B1 (ko) * 2009-06-24 2012-03-08 삼성모바일디스플레이주식회사 박막 증착 장치
JP5328726B2 (ja) 2009-08-25 2013-10-30 三星ディスプレイ株式會社 薄膜蒸着装置及びこれを利用した有機発光ディスプレイ装置の製造方法
JP5677785B2 (ja) 2009-08-27 2015-02-25 三星ディスプレイ株式會社Ｓａｍｓｕｎｇ Ｄｉｓｐｌａｙ Ｃｏ．，Ｌｔｄ． 薄膜蒸着装置及びこれを利用した有機発光表示装置の製造方法
EP2473624B1 (en) * 2009-08-31 2019-05-01 Gen-Probe Incorporated Dengue virus assay
US8876975B2 (en) 2009-10-19 2014-11-04 Samsung Display Co., Ltd. Thin film deposition apparatus
KR101084184B1 (ko) 2010-01-11 2011-11-17 삼성모바일디스플레이주식회사 박막 증착 장치
KR101174875B1 (ko) 2010-01-14 2012-08-17 삼성디스플레이 주식회사 박막 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
KR101193186B1 (ko) 2010-02-01 2012-10-19 삼성디스플레이 주식회사 박막 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
KR101156441B1 (ko) 2010-03-11 2012-06-18 삼성모바일디스플레이주식회사 박막 증착 장치
KR101202348B1 (ko) 2010-04-06 2012-11-16 삼성디스플레이 주식회사 박막 증착 장치 및 이를 이용한 유기 발광 표시 장치의 제조 방법
US8894458B2 (en) 2010-04-28 2014-11-25 Samsung Display Co., Ltd. Thin film deposition apparatus, method of manufacturing organic light-emitting display device by using the apparatus, and organic light-emitting display device manufactured by using the method
IT1400574B1 (it) 2010-05-06 2013-06-14 Freni Brembo Spa Dispositivo di frenatura a disco per veicoli
US8685649B2 (en) 2010-06-10 2014-04-01 The United States Of America As Represented By The Secretary Of The Navy RT-LAMP assay for the detection of pan-serotype dengue virus
KR101223723B1 (ko) 2010-07-07 2013-01-18 삼성디스플레이 주식회사 박막 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
WO2012045063A2 (en) * 2010-10-01 2012-04-05 University Of Rochester Flavivirus domain iii vaccine
KR101738531B1 (ko) 2010-10-22 2017-05-23 삼성디스플레이 주식회사 유기 발광 디스플레이 장치의 제조 방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
KR101723506B1 (ko) 2010-10-22 2017-04-19 삼성디스플레이 주식회사 유기층 증착 장치 및 이를 이용한 유기 발광 디스플레이 장치의 제조 방법
KR20120045865A (ko) 2010-11-01 2012-05-09 삼성모바일디스플레이주식회사 유기층 증착 장치
WO2012065105A2 (en) * 2010-11-12 2012-05-18 Thomas Monath Chimeric flavivirus vaccines
KR20120065789A (ko) 2010-12-13 2012-06-21 삼성모바일디스플레이주식회사 유기층 증착 장치
KR101760897B1 (ko) 2011-01-12 2017-07-25 삼성디스플레이 주식회사 증착원 및 이를 구비하는 유기막 증착 장치
KR101840654B1 (ko) 2011-05-25 2018-03-22 삼성디스플레이 주식회사 유기층 증착 장치 및 이를 이용한 유기 발광 디스플레이 장치의 제조 방법
KR101852517B1 (ko) 2011-05-25 2018-04-27 삼성디스플레이 주식회사 유기층 증착 장치 및 이를 이용한 유기 발광 디스플레이 장치의 제조 방법
KR101857249B1 (ko) 2011-05-27 2018-05-14 삼성디스플레이 주식회사 패터닝 슬릿 시트 어셈블리, 유기막 증착 장치, 유기 발광 표시장치제조 방법 및 유기 발광 표시 장치
KR20130004830A (ko) 2011-07-04 2013-01-14 삼성디스플레이 주식회사 유기층 증착 장치 및 이를 이용한 유기 발광 표시 장치의 제조 방법
KR101826068B1 (ko) 2011-07-04 2018-02-07 삼성디스플레이 주식회사 유기층 증착 장치
KR102015872B1 (ko) 2012-06-22 2019-10-22 삼성디스플레이 주식회사 유기층 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조 방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
US8895028B2 (en) 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
US20150265695A1 (en) * 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
KR102081284B1 (ko) 2013-04-18 2020-02-26 삼성디스플레이 주식회사 증착장치, 이를 이용한 유기발광 디스플레이 장치 제조 방법 및 유기발광 디스플레이 장치
KR20160023683A (ko) * 2013-06-21 2016-03-03 머크 샤프 앤드 돔 코포레이션 뎅기 바이러스 백신 조성물 및 그의 사용 방법
NO340722B1 (no) * 2014-06-27 2017-06-06 Norwegian Institute For Agricultural & Environmental Res Transgene planter som uttrykker et rekombinant tetravalent kimært denguevirusantigen for å fremstille effektive vaksiner avledet derfra, samt transgent plastid, plantecelle og frø, rekombinant DNA molekyl, vektor, fremgangsmåter for fremstilling og anvendelse derav
SG11201704942QA (en) 2014-12-22 2017-07-28 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
US11285202B2 (en) * 2016-01-26 2022-03-29 University Of South Carolina Polymer-protein core-shell particles as effective vaccine delivery vehicles and treatments methods using the same
EP3426292A1 (en) 2016-03-11 2019-01-16 THE UNITED STATES OF AMERICA, represented by the S Live attenuated zika virus vaccine
SG10201913383RA (en) * 2016-04-13 2020-03-30 Takeda Vaccines Inc Compositions and methods of vaccination against dengue virus in children and young adults
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
KR102494651B1 (ko) 2017-12-07 2023-01-31 머크 샤프 앤드 돔 엘엘씨 뎅기 바이러스 백신 조성물의 제제
EP3846848A4 (en) * 2018-09-04 2022-07-06 The Board of Regents of the University of Texas System DNA PLASMID INITIATED LIVE VACCINES FOR PLUS-POLARITY SINGLE STRAND RNA VIRUS
WO2021173597A1 (en) * 2020-02-28 2021-09-02 Merck Sharp & Dohme Corp. Dengue serotype specific rt-pcr multiplex assay
WO2023161715A1 (en) * 2022-02-22 2023-08-31 Futr Bio Ltda. Next generation mrna vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058444A2 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Adaptation of virus to vertebrate cells
EP1159969A1 (fr) * 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
DK2290109T3 (da) * 2001-05-22 2014-11-10 Us Gov Health & Human Serv Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira
ES2355719T3 (es) * 2002-05-03 2011-03-30 The United States Government As Represented By The Department Of Health And Human Services Vacuna contra el dengue que contiene una deleción común de 30 nucleótidos en la utr en 3' del dengue tipos 1 y 2.
US8337860B2 (en) * 2006-08-15 2012-12-25 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Development of dengue virus vaccine components

Also Published As

Publication number Publication date
CA2483653C (en) 2014-10-28
HUE037330T2 (hu) 2018-08-28
US9783787B2 (en) 2017-10-10
DE60334310D1 (de) 2010-11-04
PT2338508T (pt) 2018-05-16
US8075903B2 (en) 2011-12-13
ATE481982T1 (de) 2010-10-15
BRPI0309631A2 (pt) 2016-11-01
EP1554301B1 (en) 2010-09-22
US7517531B2 (en) 2009-04-14
USRE46631E1 (en) 2017-12-12
US20070009552A1 (en) 2007-01-11
US20200392469A1 (en) 2020-12-17
ES2677348T3 (es) 2018-08-01
US10837003B2 (en) 2020-11-17
DK2338508T3 (en) 2018-05-28
TR201806655T4 (tr) 2018-06-21
EP3763382A1 (en) 2021-01-13
CA2483653A1 (en) 2003-11-13
DK1554301T3 (da) 2011-01-24
US20180010099A1 (en) 2018-01-11
USRE46641E1 (en) 2017-12-19
ES2355719T3 (es) 2011-03-30
EP2319532A1 (en) 2011-05-11
EP2338508A1 (en) 2011-06-29
WO2003092592A2 (en) 2003-11-13
PT1554301E (pt) 2010-12-28
US20130011433A1 (en) 2013-01-10
US11753627B2 (en) 2023-09-12
AU2003231185A1 (en) 2003-11-17
BRPI0309631B1 (pt) 2021-07-20
WO2003092592A3 (en) 2005-05-19
SI2338508T1 (en) 2018-07-31
JP2005532044A (ja) 2005-10-27
US20090258036A1 (en) 2009-10-15
EP2338508B1 (en) 2018-02-14
EP1554301A2 (en) 2005-07-20
EP1554301A4 (en) 2006-11-08
SI1554301T1 (sl) 2011-01-31
CY1120558T1 (el) 2019-07-10
EP3205352A1 (en) 2017-08-16
JP4977811B2 (ja) 2012-07-18

Similar Documents

Publication Publication Date Title
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
ATE364624T1 (de) Multisystemisches kümmerwuchssyndrom durch viren in schweine
BR0111732A (pt) Prodrogas de 2-deóxi-beta-l-nucleosìdeos
UA85536C2 (en) Viral antigens
FR11C0027I2 (fr) Virus de l'influenza recombinants pour vaccins et traitement genetique
ATE297757T1 (de) Chimäre impfstoffe gegen flaviviren
WO2003048184A3 (en) Flavivirus ns1 subunit vaccine
BR0111830A (pt) Método de produção de partìculas semelhantes ao vìrus da influenza (vlps), vlps da influenza, vlps quiméricas, proteìnas da influenza, composições imunogênica e farmacêutica, métodos de imunizar contra a infecção causada pelo vìrus da influenza ou por um microorganismo patogênico outro que não o vìrus da influenza, método de tratamento, e, célula hospedeira transfectada, infectada ou transformada com uma molécula de dna recombinante
ATE310089T1 (de) Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
WO2002072803A3 (en) Subgenomic replicons of the flavivirus dengue
BR0310020A (pt) Expressão de genes no vìrus da vacìnia modificado ancara por uso do promotor de ati de vacìnia
WO2009051823A3 (en) Bacterial artificial chromosome containing feline herpes virus type 1 genome and uses thereof
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
WO2003008571A3 (es) Cadenas quiméricas codificantes para proteínas inductoras de efectos contra virus
WO1999057284A3 (en) Attenuated influenza viruses
WO2007035530A3 (en) Ancestral dengue virus envelope protein sequence
NZ511168A (en) Recombinant CELO virus and CELO virus DNA
ATE263234T1 (de) Veränderte, kleine rna-viren
DE60035680D1 (de) Komplette gensequenz des esel-leukozyten-impfstoffstammes des equinen infektiösen anemievirus und ihre anwendung
CY1117369T1 (el) Εμβολιο για τον δαγγειο πυρετο που περιεχει μια κοινη 30 νουκλεοτιδιων διαγραφη στην 3'-utr των τυπων 1 και 2 ιου του δαγγειου πυρετου
DK1254663T3 (da) Antivirusmiddel
BR0318026A (pt) Antìgenos recombinantes do vìrus da hepatite a, e, uso dos antìgenos
MY145463A (en) Flavivirus ns1 subunit vaccine
MY146370A (en) Classical swine fever tissue culture live vaccine virus, the tissue culture method of the same and classical swine fever tissue culture live vaccine comprising the same

Legal Events

Date Code Title Description
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 25/04/2023